Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
159
resultados
Última actualización
01/05/2025 [07:06:00]
Resumen de: EP4545969A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: EP4545971A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: EP4545970A2
The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.
Resumen de: AU2023286504A1
The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Resumen de: EP4545559A2
The present invention is part of the field of genetic engineering, more specifically, in the field of production of anti-sars-cov-2 human monoclonal antibodies. The neutralizing human antibodies of the present application can be used in the therapy of COVID19, avoiding hospitalization and aggravation of infected people with a predisposition to develop severe disease. Persons who are not infected but at risk (health and safety professionals, and others) may benefit from preventive treatment. The present invention also relates to a pharmaceutical composition comprising anti-SARS-COV-2 human monoclonal antibodies, as well as a diagnostic kit and use thereof.
Resumen de: WO2025084921A1
The present invention relates to the development of formulations based on the glycyrrhizic acid compound due to its antiviral, anti-inflammatory and immunomodulatory properties, as a syrup at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, as a solution for nebulising at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, and as a spray of liposomal nanoparticles at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound. Cough suppressants, bronchospasm inhibitors and anti-corticoids are added, and lastly, the pH is adjusted in a range of 4 - 7 as this is the most physiological range. The invention is for the therapeutic and prophylactic management of infections and clinical symptoms of the infection due to SARS-CoV2 and COVID-19.
Resumen de: US2025129165A1
The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.
Resumen de: US2025129438A1
A method of detecting SARS-CoV includes amplifying isothermally a target sequence in a sample with at least one set of oligonucleotide primers and assaying the sample with a SARS assay to detect the target sequence of a SARS-CoV nucleic acid sequence. A kit for detecting SARS-CoV in a sample includes a reverse transcriptase, a universal primer set suitable for loop-mediated isothermal amplification (LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof containing mutations within one or more primer binding sites.
Resumen de: US2025127881A1
The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.
Resumen de: US2025127880A1
Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.
Resumen de: US2025127890A1
Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.
Resumen de: US2025130231A1
The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.
Resumen de: WO2025083216A1
The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.
Resumen de: WO2025085665A1
A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.
Resumen de: US2025130230A1
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
Resumen de: US2025130227A1
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: US2025127744A1
The present invention relates to treating SARS-CoV-2 infection by concurrent administration of different treatment supplementation through anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The lower doses of the proposed treatment modalities in the present invention denoted anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The higher doses of the proposed treatment modalities in the present invention promoted the release the CD4+ and CD8+ T cell, increasing the phagocytosis activity for viral clearance of SARS-CoV-2 infection. The proposed treatment modalities in the present invention allow the maturation of antibodies against natural SARS-CoV-2 infection.
Resumen de: US2025127734A1
Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta+2 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.
Resumen de: US2025129368A1
The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-COV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5′ terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-COV-2.
Resumen de: AU2023356620A1
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: GB2634841A
A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump. The architecture of the neutered inactivated virus can be kept intact or partially destroyed by using graded dosage of the UVC.
Resumen de: GB2634804A
A method for predicting an interaction between a receptor-binding domain (RBD) in a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a human angiotensin-converting enzyme 2 (hACE2) receptor comprises conducting prediction simulation based on a protein structure data and comparing an obtained prediction result with surface plasmon resonance (SPR) experimental data; analysing protein structure simulation and binding simulation based on a sequence data; and analysing protein structure simulation and binding simulation based on a mutation site. The method is based on PROtein binDIng enerGY prediction (PRODIGY) and can predict an interaction mode between the RBD in the S protein and the hACE2 receptor through multiple data types, and can quickly and effectively analyse the infectivity.
Resumen de: US2021311054A1
The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-COV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.
Resumen de: WO2023242246A1
The present invention relates to methacrylate-based functionalized dendronized polyglycerol polymers. These polymers are highly biocompatible and less anticoagulant, form thread-like single chain fibers and show excellent inhibition against respiratory viruses such as SARS-CoV-2 and HSV-1. They can be easily used for forming degradable hydrogels together with a crosslinker.
Nº publicación: US12281155B1 22/04/2025
Solicitante:
INST PASTEUR [FR]
SPIKIMM [FR]
INSTITUT PASTEUR,
SPIKIMM
Resumen de: US12281155B1
The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).
BOPI
Sede Electrónica
